AKT1 and diffuse large B-cell lymphoma: miR-27b can specifically inhibit MET and the MET/PI3K/AKT pathway, thus inhibiting the proliferation of DLBCL cells and promoting the apoptosis of the cells, thus inhibiting the progression of tumors (Fig. 7).